- Home
- RFIL vs KRRO Comparison
RFIL vs KRRO Comparison
Compare RFIL & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RFIL | KRRO |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.5M | 101.1M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RFIL | KRRO |
|---|---|---|
| Price | $11.30 | $12.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $9.25 | ★ $47.10 |
| AVG Volume (30 Days) | 143.6K | ★ 209.7K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | 82.35 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $55,325,000.00 | $2,271,000.00 |
| Revenue This Year | $7.07 | $145.97 |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $1,135.00 | ★ N/A |
| Revenue Growth | ★ 10.22 | N/A |
| 52 Week Low | $3.39 | $5.20 |
| 52 Week High | $12.24 | $55.89 |
Technical Indicators
Market Signals| Indicator | RFIL | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 54.24 |
| Support Level | $6.11 | $10.55 |
| Resistance Level | $12.07 | $15.05 |
| Average True Range (ATR) | 0.87 | 0.87 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 76.64 | 55.07 |
Price Performance
Historical ComparisonAbout RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.